Dr. Douglas Thamm
You do not have permission to view this document: [5989376]!
Study Start Date: 07/01/2007
Study End Date: 07/01/2008
Novel Chemotherapy for Canine Multiple Myeloma
Although canine multiple myeloma initially responds to chemotherapy, virtually all patients will eventually relapse, and novel treatments are needed. This study is evaluating a novel chemotherapy drug for the treatment of multiple myeloma in dogs. Previously untreated dogs, or dogs having failed other forms of therapy are eligible. The study is funded by a biopharmaceutical company that wishes to remain anonymous for proprietary reasons.
Study Design:
Prospective trial
Sample Size:
6 (3 have been enrolled to date)
Inclusion criteria:
Dogs must have confirmed multiple myeloma, and must be treated either at Colorado State University in Fort Collins, CO or at University of Wisconsin in Madison, WI.
Exclusion Criteria:
Dogs must be free of severe intercurrent disease, and must have adequate renal, hepatic and hematologic function. A 3-week washout is necessary following any previous chemotherapy.
Study Controls:
Not applicable
Costs/Reimbursements:
All costs associated with the study (initial staging, treatment, monitoring, management of adverse events) are paid by the Sponsor. In addition, owners will receive $1,000 in hospital credit that can be put toward additional therapy at the time of treatment failure.
You do not have permission to view this document: [5955220]!
Full Disclosure information:
- The study is funded by a biopharmaceutical company.
- The investigator lectures on this topic with corporate sponsorship.
- The investigators do not have any conflict of interest.
- The study will not be reported on VIN.
- The authors will acknowledge VIN if the study is published.